Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation

doi:10.4251/wjgo.v17.i11.112689

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(46)

(82)

(0)

(12)

(1)

(747)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Nov 15, 2025; 17(11): 112689
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.112689

Full Size Figure Download Figure

Figure 1 Flowchart of patient enrollment and exclusion. This flowchart outlines the enrollment and exclusion process for patients with hepatitis B virus-related cirrhosis and hepatocellular carcinoma who received radiofrequency ablation at Tianjin Third Central Hospital from August 2018 to December 2020. HCC: Hepatocellular carcinoma; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide fumarate; HCV: Hepatitis C virus; TACE: Transcatheter arterial chemoembolization.

Citation: Xu BG, Zhang X, Liu F, Li FH, Zhang X, Xiang HL, Liang J. Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. World J Gastrointest Oncol 2025; 17(11): 112689
URL: https://www.wjgnet.com/1948-5204/full/v17/i11/112689.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.112689

Xu BG, Zhang X, Liu F, Li FH, Zhang X, Xiang HL, Liang J. Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. World J Gastrointest Oncol 2025; 17(11): 112689 [PMID: 41281477 DOI: 10.4251/wjgo.v17.i11.112689]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.